NFKB1 and myelodysplastic syndrome: MDS HSCs preferentially exhibit noncanonical activation of NF-κB, over the canonical NF-κB activation of normal HSCs and inhibition of noncanonical NF-κB signaling abrogates their competitive advantage [75,76].